Journal of Innovation in Applied Research (eISSN: 2581-4206)

						<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="medical-biotechnology" lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher">JIAR</journal-id>
      <journal-id journal-id-type="nlm-ta">Journ of innovation in applied research</journal-id>
      <journal-title-group>
        <journal-title>Journal of Innovation in Applied Research</journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Journ of innovation in applied research</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2231-2196</issn>
      <issn pub-type="opub">0975-5241</issn>
      <publisher>
        <publisher-name>Radiance Research Academy</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">62</article-id>
      <article-id pub-id-type="doi"> 10.51323/JIAR.3.1.2020.15-21</article-id>
      <article-id pub-id-type="doi-url"/>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Medical Biotechnology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Biology and Metabolism of Human Lung Carcinoma: Review&#13;
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kushwaha</surname>
            <given-names>Reshma</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>1</day>
        <month>01</month>
        <year>1970</year>
      </pub-date>
      <volume>3</volume>
      <issue/>
      <fpage>15</fpage>
      <lpage>21</lpage>
      <permissions>
        <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Cancer is the subsequent driving reason for death globally and is answerable for an expected 9.6 million death is because of cancer. The main reason for high mortality due to lung cancer is Attributable to the fact that the diagnosis is made when cancer spread beyond the curable stage and cannot be treated by surgical, chemical or radiation therapy. The data of GLOBOCAN indicates that this disease has recorded highest mortality rate among all different types of cancer. Lung tumor cell shows intensive metabolic changes, permitting them to fulfill the metabolic requirements that arises the proliferation and extra features of threat. Such a metabolic change is coordinated by the genetic changes that drive tumorigenesis, that is, the inducement of oncogenes or potentially the loss of onco-suppressor genes, and further formed by natural signals, for example, oxygen availability and supplement accessibility. Understanding this metabolic pathway is basic to explain the central components of tumorigenesis just as to discover novel, medicinal exploitable liabilities of cancer cells. In spite of the fact that these discoveries prompted a reestablished enthusiasm for malignant growth metabolism, our insight on the particulars of tumor metabolism is as yet divided. This review paper shows recent discoveries identified with key transcription factors and enzymes that assume a significant contribution in the regulation of lung cancer metabolism.&#13;
&#13;
Keywords: Lung Cancer, Metabolism, Oncogene, Tumorigenesis, Transcription Factor.&#13;
</p>
      </abstract>
      <kwd-group>
        <kwd>Lung Cancer</kwd>
        <kwd> Metabolism</kwd>
        <kwd> Oncogene</kwd>
        <kwd> Tumorigenesis</kwd>
        <kwd> Transcription Factor</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
					

REFERENCE

Smith, R. D., & Mallath, M. K. (2019). History of the Growing Burden of Cancer in India: From Antiquity to the 21st Century. Journal of Global Oncology, (5), 1–15.

Martel, C. D., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020). Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. The Lancet Global Health, 8(2).

Cancer today. Retrieved from http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424.

Lemjabbar-Alaoui, H., Hassan, O. U. I., Yang, Y.-W., & Buchanan, P. (2015). Lung cancer: Biology and treatment options.

Vanhove, K., Graulus, G. J., Mesotten, L., Thomeer, M., Derveaux, E., Noben, J. P., Guedens, W., & Adriaensens, P. (2019). The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. Frontiers in oncology, 9, 1215.

Anastasiou, D. (2016). Tumour microenvironment factors shaping the cancer metabolism landscape. British Journal of Cancer, 116(3), 277–286.

Ahn, C. S., & Metallo, C. M. (2015). Mitochondria as biosynthetic factories for cancer proliferation. Cancer & metabolism, 3(1), 1.

Clinical significance of ras oncogene activation in human lung cancer. (1993). Lung Cancer, 8(5-6), 338.

Massarelli, E., & Papadimitrakopoulou, V. A. (2012). Phosphatidykinosital 3-Kinase and Mammalian Target of Rapamycin Pathway in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 7(12).

Semenza, G. L. (2009). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 29(5), 625–634.

Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. (1993). Lung Cancer, 10(1-2), 128–129.

Takashima, A., & Faller, D. V. (2013). Targeting the RAS oncogene. Expert opinion on therapeutic targets, 17(5), 507–531.

West, J. B. (2017). Physiological Effects of Chronic Hypoxia. New England Journal of Medicine, 376(20), 1965–1971.

Miller, D. M., Thomas, S. D., Islam, A., Muench, D., & Sedoris, K. (2012). c-Myc and cancer metabolism. Clinical cancer research: an official journal of the American Association for Cancer Research, 18(20), 5546–5553.

Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015). MYC, Metabolism, and Cancer. Cancer discovery, 5(10), 1024–1039.

De Berardinis R. J. (2008). Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genetics in medicine: official journal of the American College of Medical Genetics, 10(11), 767–777.